Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis (Q39251941)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

10 September 2017

Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis (English)

1 reference

Europe PubMed Central

10 September 2017

0 references

steatohepatitis

0 references

non-alcoholic steatohepatitis

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

S A Harrison

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

S R Marri

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

N Chalasani

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

W Aronstein

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

G A Thompson

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

W Irish

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

M V Miles

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

S A Xanthakos

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

E Lawitz

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

M Noureddin

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

T D Schiano

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

M Siddiqui

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

A Sanyal

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

B A Neuschwander-Tetri

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

P G Traber

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

0 references

publication date

24 October 2016

1 reference

Europe PubMed Central

10 September 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

44

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

11-12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1183-1198

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

When galectins recognize glycans: from biochemistry to physiology and back again

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Galectin-3 regulates myofibroblast activation and hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Deficiency in galectin-3 promotes hepatic injury in CDAA diet-induced nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Galectin-3 Ablation Enhances Liver Steatosis, but Attenuates Inflammation and IL-33-Dependent Fibrosis in Obesogenic Mouse Model of Nonalcoholic Steatohepatitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Therapy of experimental NASH and fibrosis with galectin inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Drug Accumulation

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Meta-analyses of FibroTest diagnostic value in chronic liver disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

α-2-Macroglobulin: a physiological guardian.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Comparison of coenzyme Q10 plasma levels in obese and normal weight children

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Alpha-2-macroglobulin and hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13816

21 January 2018

Identifiers

10.1111/APT.13816

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27778367%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39251941&oldid=1988617144"